Glenmede Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Glenmede Trust’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,236	Closed	-$1.88M	–	1367
2021 Q2	$1.88M	Sell	10,236 -321	-3%	-$55.1K	0.01%	546
2021 Q1	$1.61M	Sell	10,557 -66,140	-86%	-$10.2M	0.01%	569
2020 Q4	$12M	Sell	76,697 -86,165	-53%	-$11.1M	0.07%	302
2020 Q3	$18.6M	Buy	162,862 +4,951	+3%	+$534K	0.11%	207
2020 Q2	$17.7M	Sell	157,911 -443,142	-74%	-$47M	0.11%	231
2020 Q1	$65M	Hold	601,053	–	–	0.3%	91
2019 Q4	$65M	Buy	601,053 +581,631	+2,995%	+$62.2M	0.3%	91
2019 Q3	$1.9K	Buy	19,422 +12,057	+164%	+$1.36M	0.01%	625
2019 Q2	$964	Sell	7,365 -167	-2%	-$21.5K	﹤0.01%	756
2019 Q1	$1.02K	Buy	7,532 +2,461	+49%	+$306K	﹤0.01%	742
2018 Q4	$491	Buy	5,071 +2,951	+139%	+$349K	﹤0.01%	858
2018 Q3	$294K	Sell	2,120 -9,739	-82%	-$1.22M	﹤0.01%	1025
2018 Q2	$1.47M	Buy	11,859 +3,815	+47%	+$446K	0.01%	645
2018 Q1	$961K	Hold	8,044	–	–	﹤0.01%	785
2017 Q4	$961K	Sell	8,044 -58	-0.7%	-$7.06K	﹤0.01%	785
2017 Q3	$1.14M	Buy	8,102 +5,919	+271%	+$804K	0.01%	738
2017 Q2	$264K	Hold	2,183	–	–	﹤0.01%	1118
2017 Q1	$264K	Buy	2,183 +138	+7%	+$17.8K	﹤0.01%	1118
2016 Q4	$250K	Sell	2,045 -863	-30%	-$106K	﹤0.01%	1148
2016 Q3	$356K	Hold	2,908	–	–	﹤0.01%	1019
2016 Q2	$339K	Sell	2,908 -169	-5%	-$24K	﹤0.01%	1033
2016 Q1	$427K	Buy	3,077 +849	+38%	+$125K	﹤0.01%	961
2015 Q4	$424K	Sell	2,228 -40	-2%	-$6.99K	﹤0.01%	983
2015 Q3	$354K	Sell	2,268 -25	-1%	-$4.56K	﹤0.01%	1036
2015 Q2	$413K	Hold	2,293	–	–	﹤0.01%	1026
2015 Q1	$397K	Sell	2,293 -378	-14%	-$68.4K	﹤0.01%	1051
2014 Q4	$493K	Buy	2,671 +260	+11%	+$48.2K	﹤0.01%	964
2014 Q3	$399K	Hold	2,411	–	–	﹤0.01%	946
2014 Q2	$375K	Hold	2,411	–	–	﹤0.01%	973
2014 Q1	$365K	Sell	2,411 -64	-3%	-$10.2K	﹤0.01%	972
2013 Q4	$328K	Sell	2,475 -80	-3%	-$9.6K	﹤0.01%	996
2013 Q3	$295K	Buy	2,555 +960	+60%	+$105K	﹤0.01%	1009
2013 Q2	$146K	Buy	+1,595	New	+$154K	﹤0.01%	1195

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return